nach oben

Erschienen in:

18.02.2021 | Clinical trial

Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy

verfasst von: Loai Saleh Albinsaad, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sei-Hyun Ahn, Sae Byul Lee

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients.

Methods

We retrospectively reviewed 594 patients diagnosed with stage I–III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups.

Results

At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(−)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(−) and 92.1% in the p53(+) group (p = 0.005). BCSS was 96.2% in the p53(−) group and 93% in the p53(+) group (p = 0.008).

Conclusion

High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.

Beslija S et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20(11):1771–1785. https://doi.org/10.1093/annonc/mdp261CrossRefPubMed

Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L (2016) Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going. Cancer Treat Rev 46:20–26. https://doi.org/10.1016/j.ctrv.2016.03.012CrossRefPubMed

Abe O et al (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467. https://doi.org/10.1016/S0140-6736(97)11423-4CrossRef

Boughey JC et al (2014) Tumor biology correlates with rates of breastconserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer findings from the ACOSOG Z1071 (alliance) prospective multicenter clinical trial. Ann Surg 260(4):608–616. https://doi.org/10.1097/SLA.0000000000000924CrossRefPubMedPubMedCentral

von Minckwitz G et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. https://doi.org/10.1200/JCO.2011.38.8595CrossRef

Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (London, England) 384(9938):164–172. https://doi.org/10.1016/S0140-6736(13)62422-8CrossRef

Koboldt DC et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. https://doi.org/10.1038/nature11412CrossRef

Rossner P Jr et al (2009) Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med 13(9b):3847–3857. https://doi.org/10.1111/j.1582-4934.2008.00553.xCrossRefPubMed

Bertheau P et al (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360(9336):852–854. https://doi.org/10.1016/S0140-6736(02)09969-5CrossRefPubMed

10.

Elledge RM, Allred DC (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52(1–3):79–98. https://doi.org/10.1023/a:1006163101948CrossRefPubMed

11.

Olivier M et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12(4):1157–1167. https://doi.org/10.1158/1078-0432.CCR-05-1029CrossRefPubMed

12.

Basho RK et al (2016) Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget 7(47):76362–76373. https://doi.org/10.18632/oncotarget.12987CrossRefPubMedPubMedCentral

13.

Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9(6):606–616. https://doi.org/10.1634/theoncologist.9-6-606CrossRefPubMed

14.

Nicolini A, Carpi A, Tarro G (2006) Biomolecular markers of breast cancer. Front Biosci 11:1818–1843. https://doi.org/10.2741/1926CrossRefPubMed

15.

Abubakar M et al (2019) Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. npj Breast Cancer 5(1):20. https://doi.org/10.1038/s41523-019-0117-7CrossRefPubMedPubMedCentral

16.

Bouchalova P et al (2014) Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. J Pathol 233(3):238–246. https://doi.org/10.1002/path.4356CrossRefPubMed

17.

Barbareschi M (1996) Progn. value immunohistochem. expr. p53 breast carcinomas a rev. lit. involv. over 9,000 patients. 4(2):106–116 (1996)

18.

Mirza AN, Mirza NQ, Vlastos G, Singletary SE (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235:1CrossRef

19.

Bae SY, Lee JH, Bae JW, Jung SP (2020) Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer. Ann Surg Treat Res 98(6):291–298. https://doi.org/10.4174/astr.2020.98.6.291CrossRefPubMedPubMedCentral

Titel: Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy
verfasst von: Loai Saleh Albinsaad
Jisun Kim
Il Yong Chung
Beom Seok Ko
Hee Jeong Kim
Jong Won Lee
Byung Ho Son
Sei-Hyun Ahn
Sae Byul Lee
Publikationsdatum: 18.02.2021
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-021-06134-6

Springer Medizin

Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy